Large NHS Trial Finds Multi-Cancer Blood Test Did Not Meet Main Goal

1-Minute Brief

The trial's outcome raises questions about the effectiveness of blood-based cancer screening for reducing late-stage diagnoses.

Key Facts

• A clinical trial of the Galleri multi-cancer blood test involved 142,000 NHS patients in the UK.
• The test was designed to detect more than 50 types of cancer from a single blood sample.
• Results were presented at a major oncology conference in Chicago.
• The trial found that the Galleri test did not reduce late-stage cancer diagnoses, its primary aim.
• Some researchers described the test as 'feasible at scale' for NHS use.

What Happened

A large clinical trial of the Galleri blood test, which screens for over 50 cancers, did not achieve its main goal of reducing late-stage cancer diagnoses among NHS patients, according to results presented at an oncology conference.

Why It Matters

The findings may influence future adoption of blood-based multi-cancer screening in public health systems and guide further research on early cancer detection technologies.

What's Next

Researchers and policymakers are expected to review the trial data to determine the future role of such tests in cancer screening programs. Further studies may be conducted to assess improvements or alternative approaches.